Herein, network pharmacology analysis identified the MAPK signaling pathway as one of the critical pathways in the therapeutic effect of ZL on DCM, with P38MAPK and TNF-α emerging as key targets. The gene discussed is TNF; the disease is familial dilated cardiomyopathy.